Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin

IJU Case Reports

article

Yoshiyuki Miyazawa¹  Takanori Shimizu¹  Yoshitaka Sekine¹  Seiji Arai¹  Akira Ohtsu¹  Yuji Fujizuka¹  Masashi Nomura¹  Hidekazu Koike¹  Hiroshi Matsui¹  Kazuhiro Suzuki¹ 

[1] Department of Urology, Gunma University Graduate School of Medicine

关键词: prostate cancer;    castration-resistant prostate cancer;    neuroendocrine prostate cancer;    poly(adenosine diphosphate-ribose) polymerase;    BRCA;   

DOI  :  10.1002/iju5.12543

学科分类：社会科学、人文和艺术（综合）

来源: Wiley

【 摘 要 】

IntroductionSeveral prostate cancers carry homologous recombination repair mutations that respond to olaparib. Because of the mechanism, the efficacy of platinum-based therapy can be used to predict the efficacy of poly(adenosine diphosphate-ribose) polymerase inhibitors such as olaparib. Case presentationWe experienced two neuroendocrine prostate cancer patients who achieved a response duration of more than 1 year with platinum-based therapy. Case 1 had a BRCA2 mutation in the germline and case 2 had a BRCA2 mutation in a somatic chromosome only. Both patients responded well to olaparib. ConclusionCisplatin and olaparib may overlap in response due to their medicinal action. It may be useful to consider genetic testing in some CRPC patients who have responded to cisplatin.

【 授权许可】

CC BY|CC BY-NC|CC BY-NC-ND